11/4/2026

speaker
Conference Operator
Operator

Hello and welcome to Nuvation Bio's third quarter 2026 financial results and business update call. Today's call is being recorded and a replay will be available on the company's website. All participants are currently in a listen-only mode. A brief question and answer session will follow the prepared remarks. Now, I'd like to turn the call over to J.R. DeVita, Vice President of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead.

speaker
J.R. DeVita
Vice President, Corporate Development and Investor Relations

Thank you, and good afternoon, everyone. Earlier today, we issued a press release summarizing our financial results for the quarter ending September 30, 2026, and provided a business update. The press release is available on the investor section of our website at newvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of iptrosi and safucitinib, our development plans for talotrectinib, safucitinib, and our drug-drug conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue, Our expected milestone payments and spending patterns and our cash runway and profitability potential. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our founder, president, and chief executive officer, Dr. David Hung, our chief commercial officer, Colleen Sjogren, and our chief financial officer, Philippe Sauvage. Now I'll turn the call over to Dr. David Hung. David, please go ahead.

speaker
Dr. David Hung
Founder, President and Chief Executive Officer

Thanks, JR. Good afternoon, everyone, and thank you all for joining us. Today, I'm pleased to discuss the progress we made across our business in the third quarter. We generated $45 million in overall revenue, driven by another quarter of strong and prosy growth. Net U.S. Ibtrozi product revenue was $27.5 million, which represented 18% growth from the last quarter. Approximately 160 new patients started treatment with Ibtrozi, about 65% of which were in the first-line setting. The commercial signals that matter most to our long-term thesis remain encouraging. 15 months into our U.S. launch, we continue to both build a growing base of patients on therapy and strengthen our position in the ROS1 market. Ibtrosi has reached an all-time high in its share of active patients receiving a ROS1 TKI and continues to lead in first-line new patient starts with greater than 60% market share as of the end of the quarter. Our revenue growth reflects an expanding active treatment base driven by an increasing proportion of first-line patients that we believe can stay on therapy for years, as seen in our trust clinical studies. Acuvia claims data from the third quarter demonstrated a 15% decline in total new patient starts across the ROS1 TKI market. This is further evidenced by a lower volume of ROS1 positive testing alerts from our laboratory data partners. We believe these observations suggest that at least part of the softness in our first-line new patient starts is a reflection of the overall flow of newly identified and treated patients, rather than a loss of Dabtrosi's competitive position. Despite the market dynamics described, as of the end of the quarter, we maintain our strong position as the leading ROS1 TKI in total active patients across all lines of therapy combined. Rothman-positive lung cancer is an ultra-rare disease, and the number of new patients entering treatment can fluctuate from quarter to quarter. We do not believe OneQuarter provides sufficient data to establish an identifiable demand trend nor draw clear conclusions. We are monitoring market activity and treatment patterns closely while maintaining our focus on the drivers we can influence, identifying patients earlier, educating physicians about appropriate testing, supporting biomarker-informed treatment decisions, and increasing appropriate use of targeted therapy. We also are encouraged by how Ibtrozi's launch compares with historical targeted lung cancer launches, particularly given the small RAS1 population and fragmented prescriber base. While we realize comparisons are nuanced due to differences in size of patient populations, cost of therapy, and initially approved lines of therapy, we believe this is helpful to put Ibtrozi's launch in context. For example, five full quarters into the launches of Labrena and Alcensa for ALK-positive lung cancer, U.S. net revenues per SEC filings and financial reports were $25 million and $36 million, respectively. As you know, Ibtrozi has already reached similar levels of sales in a more competitive market despite Roslin incidents being approximately half that of ALK. Thank you for watching. Most fundamentally, our confidence begins with the clinical profile. In TKI-naive patients in Trust 1, Ibtrosi demonstrated a 90% objective response rate or ORR, 50 months of median duration of response or DOR, and 50 months of median progression-free survival or PFS. Its tolerability profile, including the unique absence of a CNS warning and precaution in the label, is another critical point of differentiation among brain penetrant ROS1 TKIs. And remember, these metrics are supported by median patient follow-up of 51 months in the TRUST1 study. We believe these attributes can support physician confidence, sustained first-line adoption, and meaningful time on therapy. This clinical profile is also one of the reasons we chose to develop Iptrosi in the adjuvant setting. Well, we're encouraged that enrollment is fully on track in this first of its kind study for ROS1. If approved, this indication could expand the patient population if Trosi is able to address, and the data from Eli Lilly's libretto study in RET-positive non-small cell lung cancer has given us even more confidence that we could reach a meaningful result in ROS1 sooner than we initially thought. Taking together, the results reinforce our view that we are building a durable commercial franchise and that Petrosi has become the standard of care in ROS1-positive lung cancer. Quarterly new patient activity will not always move in a straight line, but our competitive positioning, growing active patient base, and ability to reach more eligible patients provide a strong foundation for the years ahead. Moving to safucitinib, we remain very excited about this program and its potential to become a key value driver for innovation bio as we move to 2027 and beyond. In August, the FDA granted fast track designation to safucitinib for the treatment of IDH1 mutant glioma. We view this as supportive external validation of both the unmet need in this disease and the potential development path for safucitinib. Fast Track designation is intended to facilitate development and expedite review of therapies that may address serious conditions with unmet medical need. And we are pleased to have this designation as we continue to advance the program. As a reminder, in July, we announced updated long-term results from the Phase 2 J201 study in 27 patients with chemotherapy and radiotherapy-naive grade 2 IDH1 mutant glioma. With a median follow-up of 39 months, the centrally assessed ORR increased to 52% from 44% at 28 months of median follow-up, Medium PFS had not yet been reached, and the 36-month PFS rate was 79%. Responses in the study have continued to deepen, and no new safety signals were observed with additional follow-up. We will present more detailed data beyond these top-line results at the Society for Neuro-Oncology annual meeting next week. As a result of this encouraging data set, we recently announced an enhanced development plan that allows us to address two key goals. First, our four studies together address all grades and risk groups within the broad IDH1 mutant glioma landscape. Second, two of these studies focus on patient groups with high unmet needs and no alternative treatment options and evaluate ORR as a primary endpoint, which will allow us to generate data quickly. In fact, these two studies in patients with grade 3 oligodendroglioma and in patients who have progressed following treatment with voracitinib also analyze tumor growth rate or TGR as a secondary endpoint, which may provide an even earlier signal of efficacy. This is a key difference from our other two pivotal randomized studies, which evaluate PFS as a primary endpoint and will not generate data until 2029 or later. As a reminder, these pivotal studies include SIGMA, which is evaluating saflucitinib in patients with high-grade and high-risk astrocytoma, and a separate study in patients with grade 2 IDH1 mutant glioma. Enrollment in the SGMA study, including the exploratory cohort, is on track, and we expect to be enrolling patients in all four studies in the coming months. We plan to provide more specific updates on enrollment and clarity around timing of data readouts next year. Finally, we also remain on track to provide an update on our drug-drug conjugate or DDC platform by the end of the year. This update will include additional detail on how we plan to move the program forward and into the clinic. We're excited by the progress of this program and look forward to sharing more information soon. Overall, the third quarter reinforced the long-term opportunity in front of us. Ibtrozi is now a commercial leader with a growing active patient base that is driven by an increasing number of new first-line patients and their long duration of treatment. Safucetinib continues to advance as a meaningful second franchise with potential data next year, and our DDC platform could contribute to future pipeline growth. With that, I'll turn the call over to Colleen to provide a more detailed update on Ibtrozi's commercial launch.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation